blood flow

In this second of two fall reports on treatment development for Duchenne muscular dystrophy, news about ARM210, CAP-1002, PDE5 inhibitors, drisapersen and CAT-1004 is presented

posted on December 4, 2014 - 3:13pm
  Update (Feb. 6, 2015): This article has been amended to show that Catabasis' compound CAT-1004 is expected to move into clinical testing in boys with DMD during the first half of 2015. =======================================================================================================================

Pharmaceutical company Eli Lilly is conducting a trial of tadalafil, which may help regulate blood flow to muscles, in some 300 boys with Duchenne MD

posted on December 11, 2013 - 11:18am
Multinational pharmaceutical company Eli Lilly is conducting a phase 3 trial of the drug tadalafil in approximately 300 boys with Duchenne muscular dystrophy (DMD) who are 7-14 years old, able to walk, have adequate cardiac function and meet other study criteria.

People with Becker MD are invited to participate in a trial to determine whether a drug that increases nitric oxide levels can improve blood-flow regulation

posted on October 14, 2013 - 5:00am
Update (Jan. 7, 2014): This trial is now closed to new participants. A new drug trial is now under way at Cedars-Sinai Medical Center in Los Angeles for men with Becker muscular dystrophy (BMD) who meet study criteria.
posted on March 31, 2011 - 11:42am
QUEST Vol. 18, No. 2
Ronald Victor admits it: He never set out to study muscular dystrophy. As an adult cardiologist specializing in hypertension (high blood pressure) and neurologic control of cardiovascular mechanisms, he’s a relative latecomer to the muscle field, but far from a reluctant one.

The vasodilating drug tadalafil (Cialis) will be tested in men with Becker muscular dystrophy to see if it improves blood flow to forearm muscles

posted on March 24, 2010 - 9:15am
Update (Oct. 8, 2012): This story has been updated to reflect that the tadalafil trial in BMD has been slightly revised and is now open. In June 2012, it had temporarily closed to new participants. The investigators say the revised trial design was necessary because they were unable to obtain access to the MRI machine for the time periods that were necessary in the first design.

Intravenous gentamicin increased dystrophin production in six of 12 boys with nonsense-mutation DMD but failed to improve strength or function at the doses used

posted on March 23, 2010 - 3:02pm
An MDA-supported clinical trial of intravenous gentamicin in children and adolescents with a form of Duchenne muscular dystrophy (DMD) caused by so-called "nonsense" mutations (also called "premature stop codon" mutations) found the drug was safe and that levels of the muscle protein dystrophin increased in some, but not all, participants who received the drug for six months.